Clinical trials: Obesity or Overweight
Overweight or Obesity
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）
This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy and safety of the oral small molecule MDR-001 Tablets over 52 weeks as an adjunct to a lifestyle intervention…
- Trial name
- NCT07274137
- Testing
- MDR-001
- Where
- 45 sites in China
- Volunteers
- 738 people
- Sponsor
- MindRank AI Ltd
Obesity
Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)
Study medicine will be given alone, or in combination with either sibutramine or orlistat, to obese subjects to compare the effect on body weight over a six month period.
- Trial name
- NCT00533481
- Testing
- MK0557
- Volunteers
- 497 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM
This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo.
- Trial name
- VESPER-2 (NCT06897202)
- Testing
- MET097 Injection
- Where
- 29 sites in United States
- Volunteers
- 133 people
- Sponsor
- Pfizer
Overweight, Obesity
Effect of Maridebart Cafraglutide on the Heart's Electrical Activity
The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in…
- Trial name
- NCT07229157
- Testing
- Maridebart Cafraglutide, Moxifloxacin
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Amgen
Healthy Subjects, Obesity
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects.
- Conditions
- Healthy Subjects, Obesity, Type 2 Diabetes
- Trial name
- NCT05822544
- Testing
- TLC-6740 Oral Solution, TLC-6740 Tablet, Drug Metabolizing Enzyme
- Where
- 4 sites in New Zealand
- Volunteers
- 564 people, healthy volunteers welcome
- Sponsor
- OrsoBio, Inc
Nausea and Vomiting, Obesity
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one…
- Trial name
- NCT07446439
- Testing
- Tradipitant
- Where
- 10 sites in United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Obesity
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®).
- Trial name
- COURAGE (NCT06299098)
- Testing
- Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 1,005 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Overweight, Obesity
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.
- Trial name
- NCT07523711
- Testing
- COC, Maridebart Cafraglutide
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Amgen
Hypertension
A Study of VCT220 in Participants With Hypertension and Obesity or Overweight
The purpose of this study is to explore the safety and efficacy of VCT220 for the treatment of hypertension in participants with obesity or overweight.
- Trial name
- VICTOR-HTN (NCT07360275)
- Testing
- VCT220 Tablet
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Vincentage Pharma Co., Ltd
Overweight and/or Obesity, Weight Management
A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity
- Trial name
- NCT07243171
- Testing
- ecnoglutide tablets
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Obesity, Overweight
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight…
- Conditions
- Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- NCT07670416
- Testing
- Enicepatide
- Where
- 21 sites in China
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Overweight or Obesity
Effect of Akkermansia Muciniphila Akk11 on Metabolic and Gut Health in Overweight and Obese Subjects
To assess the efficacy and safety of the use of probiotics as a food supplement compared to placebo in regulating body metabolism and gut microbiota in overweight or obese subjects.
- Trial name
- NCT06653101
- Testing
- Probiotic
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Obesity, Overweight
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
- Trial name
- TRIUMPH-8 (NCT07232719)
- Testing
- Retatrutide
- Where
- 31 sites in United States, United Kingdom
- Volunteers
- 250 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
This study will look at the change in teenagers' body weight from the start to the end of the study. This is to compare the effect on body weight in teenagers taking semaglutide (a new medicine) and teenagers taking "dummy"…
- Trial name
- NCT04102189
- Testing
- Semaglutide
- Where
- 51 sites in United States, Austria and 6 more
- Volunteers
- 201 people
- Sponsor
- Novo Nordisk A/S
Obesity & Overweight
UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)
This randomized, double-blind, parallel, placebo-controlled phase Ⅲ study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients
- Trial name
- NCT07648225
- Testing
- UBT251 Injection 4.0 mg, UBT251 Injection 6.0 mg
- Where
- China
- Volunteers
- 600 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Healthy Participants
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
This study will measure the effects of multiple doses of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive (CoC) ethinyl estradiol…
- Trial name
- NCT07013643
- Testing
- AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP)
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Metabolism and Nutrition Disorder, Overweight or Obesity
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants…
- Trial name
- STEP 1 (NCT03548935)
- Testing
- Semaglutide
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 1,961 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes.
- Trial name
- NCT06901349
- Testing
- Bimagrumab, Tirzepatide
- Where
- 50 sites in United States, Argentina and 3 more
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-5817 when administered subcutaneously (SC) as single and multiple doses in adults who are affected by obesity.
- Trial name
- NCT06934408
- Testing
- HRS-5817 Injection
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Overweight, Obesity
Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity
The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity.
- Trial name
- NCT06910839
- Testing
- PF-07976016, PF-06882961
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Pfizer